Gayathri R Devi

Recent Publications: (More Publications)

• MA Morse, AC Hobeika, T Osada, P Berglund, B Hubby, S Negri, D Niedzwiecki, GR Devi, BK Burnett, TM Clay, J Smith, HK Lyerly, An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer., The Journal of clinical investigation (2010) [doi] [abs]
• KM Aird, RB Ghanayem, S Peplinski, HK Lyerly, GR Devi, X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor., Molecular cancer therapeutics, vol 9 no. 5 (2010), pp. 1432-42 [doi] [abs]
• ZC Hartman, J Wei, T Osada, O Glass, G Lei, XY Yang, S Peplinski, DW Kim, W Xia, N Spector, J Marks, W Barry, A Hobeika, G Devi, A Amalfitano, MA Morse, HK Lyerly, TM Clay, An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity., Clinical cancer research : an official journal of the American Association for Cancer Research, vol 16 no. 5 (2010), pp. 1466-77 [doi] [abs]
• T Osada, D Hsu, S Hammond, A Hobeika, G Devi, TM Clay, HK Lyerly, MA Morse, Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody., British journal of cancer, vol 102 no. 1 (2010), pp. 124-33 [doi] [abs]
• PL Iversen, KM Aird, R Wu, MM Morse, GR Devi, Cellular uptake of neutral phosphorodiamidate morpholino oligomers., Current pharmaceutical biotechnology, vol 10 no. 6 (2009), pp. 579-88 [abs]
• X Ding, AB Mohd, Z Huang, T Baba, MQ Bernardini, HK Lyerly, A Berchuck, SK Murphy, AB Buermeyer, GR Devi, MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition., British journal of cancer, vol 101 no. 2 (2009), pp. 269-77 [doi] [abs]
• JC Mavropoulos, WC Buschemeyer 3rd, AK Tewari, D Rokhfeld, M Pollak, Y Zhao, PG Febbo, P Cohen, D Hwang, G Devi, W Demark-Wahnefried, EC Westman, BL Peterson, SV Pizzo, SJ Freedland, The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model., Cancer prevention research (Philadelphia, Pa.), vol 2 no. 6 (2009), pp. 557-65 [doi] [abs]
• GR Devi, Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells., Methods in molecular biology (Clifton, N.J.), vol 542 (2009), pp. 351-61 [abs]
• KM Aird, X Ding, A Baras, J Wei, MA Morse, T Clay, HK Lyerly, GR Devi, Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression., Molecular cancer therapeutics, vol 7 no. 1 (2008), pp. 38-47 [doi] [abs]
• HS Sekhon, CA London, M Sekhon, PL Iversen, GR Devi, c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model., Lung cancer (Amsterdam, Netherlands), vol 60 no. 3 (2008), pp. 347-54 [doi] [abs]
• MA Morse, A Hobeika, T Osada, D Niedzwiecki, PK Marcom, KL Blackwell, C Anders, GR Devi, HK Lyerly, TM Clay, Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2., Journal of translational medicine, vol 5 (2007), pp. 42 [doi] [abs]
• GR Devi, siRNA-based approaches in cancer therapy., Cancer gene therapy, vol 13 no. 9 (2006), pp. 819-29 [doi] [abs]
• GR Devi, TM Beer, CL Corless, V Arora, DL Weller, PL Iversen, In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors., Clinical cancer research : an official journal of the American Association for Cancer Research, vol 11 no. 10 (2005), pp. 3930-8 [doi] [abs]
• V Arora, GR Devi, PL Iversen, Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics., Current pharmaceutical biotechnology, Netherlands, vol 5 no. 5 (2004), pp. 431-9 [abs]
• YJ Ko, GR Devi, CA London, A Kayas, MT Reddy, PL Iversen, GJ Bubley, SP Balk, Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers., The Journal of urology, United States, vol 172 no. 3 (2004), pp. 1140-4 [abs]
• A Amantana, CA London, PL Iversen, GR Devi, X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells., Molecular cancer therapeutics, United States, vol 3 no. 6 (2004), pp. 699-707 [abs]
• GR Devi, XIAP as target for therapeutic apoptosis in prostate cancer., Drug news & perspectives, Spain, vol 17 no. 2 (2004), pp. 127-34 [abs]
• CA London, HS Sekhon, V Arora, DA Stein, PL Iversen, GR Devi, A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity., Cancer gene therapy, England, vol 10 no. 11 (2003), pp. 823-32 [abs]
• PL Iversen, V Arora, AJ Acker, DH Mason, GR Devi, Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans., Clinical cancer research : an official journal of the American Association for Cancer Research, United States, vol 9 no. 7 (2003), pp. 2510-9 [abs]
• DC Knapp, JE Mata, MT Reddy, GR Devi, PL Iversen, Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model., Anti-cancer drugs, England, vol 14 no. 1 (2003), pp. 39-47 [abs]
• GR Devi, JR Oldenkamp, CA London, PL Iversen, Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells., The Prostate, United States, vol 53 no. 3 (2002), pp. 200-10 [abs]
• GR Devi, CC Sprenger, SR Plymate, RG Rosenfeld, Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo., The Prostate, United States, vol 51 no. 2 (2002), pp. 141-52 [abs]
• GR Devi, Prostate cancer: status of current treatments and emerging antisense-based therapies., Current opinion in molecular therapeutics, England, vol 4 no. 2 (2002), pp. 138-48 [abs]
• GR Devi, DL Graham, Y Oh, RG Rosenfeld, Effect of IGFBP-3 on IGF- and IGF-analogue-induced insulin-like growth factor-I receptor (IGFIR) signalling., Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, Scotland, vol 11 no. 4 (2001), pp. 231-9 [abs]
• A López-Bermejo, CK Buckway, GR Devi, V Hwa, SR Plymate, Y Oh, RG Rosenfeld, Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium., Endocrinology, UNITED STATES, vol 141 no. 11 (2000), pp. 4072-80 [abs]
• GR Devi, DH Yang, RG Rosenfeld, Y Oh, Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling., Endocrinology, UNITED STATES, vol 141 no. 11 (2000), pp. 4171-9 [abs]
• RG Rosenfeld, V Hwa, L Wilson, A Lopez-Bermejo, C Buckway, C Burren, WK Choi, G Devi, A Ingermann, D Graham, G Minniti, A Spagnoli, Y Oh, The insulin-like growth factor binding protein superfamily: new perspectives., Pediatrics, UNITED STATES, vol 104 no. 4 Pt 2 (1999), pp. 1018-21 [abs]
• GR Devi, AT De Souza, JC Byrd, RL Jirtle, RG MacDonald, Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers., Cancer research, UNITED STATES, vol 59 no. 17 (1999), pp. 4314-9 [abs]
• JC Byrd, GR Devi, AT de Souza, RL Jirtle, RG MacDonald, Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations., The Journal of biological chemistry, UNITED STATES, vol 274 no. 34 (1999), pp. 24408-16 [abs]
• GR Devi, JC Byrd, DH Slentz, RG MacDonald, An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor., Molecular endocrinology (Baltimore, Md.), UNITED STATES, vol 12 no. 11 (1998), pp. 1661-72 [abs]
• F Garmroudi, G Devi, DH Slentz, BS Schaffer, RG MacDonald, Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding., Molecular endocrinology (Baltimore, Md.), UNITED STATES, vol 10 no. 6 (1996), pp. 642-51 [abs]